Newsfeeds - Spark Newswire

5 minute read

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer’s Sleep Disorder Drug Filing Accepted For Review, Voyager’s Licensing Options Deal

Today, 3:48 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5)

ABEO

2 minute read

News

MediWound Announces Peer-Reviewed Publication Of EscharEx In-Vivo Head-To-Head Comparator Study In The Journal Of Wound Care

By Benzinga Newsdesk

Today, 3:48 AM

MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced a peer-reviewed publication in the

MDWD

1 minute read

Aegis Capital Maintains Buy on MediWound, Lowers Price Target to $9

By Benzinga Newsdesk

Today, 3:48 AM

Aegis Capital maintains MediWound (NASDAQ:MDWD) with a Buy and lowers the price target from $10 to $9.

MDWD

1 minute read

HC Wainwright & Co. Maintains Buy on MediWound, Lowers Price Target to $6.5

By Benzinga Newsdesk

Today, 3:48 AM

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains MediWound (NASDAQ:MDWD) with a Buy and lowers the price target from $7 to $6.5.

MDWD

1 minute read

MediWound Q2 EPS $(0.12) Misses $(0.07) Estimate, Sales $6.10M Beat $5.63M Estimate

By Benzinga Newsdesk

Today, 3:48 AM

MediWound (NASDAQ:MDWD) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.07) by 71.43 percent. This is a 9.09 percent decrease over losses of $(0.11) per share from the

MDWD

10 minute read

Earnings Scheduled For August 10, 2021

By Benzinga Insights

Today, 3:48 AM

Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter.

ABST

2 minute read

Earnings

MediWound’s Earnings: A Preview

By Benzinga Insights

Today, 3:48 AM

On Tuesday, August 10, MediWound (NASDAQ:MDWD) will release its latest earnings report. Benzinga's outlook for MediWound is included in the following report.

MDWD

1 minute read

MediWound Starts Testing MW005 In Two Mid-Stage Trials In Patients With Non-Melanoma Skin Cancer

By Vandana Singh

Today, 3:48 AM

MediWound Ltd (NASDAQ:MDWD) has initiated a Phase 1/2 study of MW005 to treat low-risk Basal Cell Carcinoma (BCC). In parallel, an…

MDWD

5 minute read

The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer’s Conference, IPOs and More

By Shanthi Rexaline

Today, 3:48 AM

Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start to the pharma reporting season.

ABBV

3 minute read

28 Stocks Moving in Wednesday’s Pre-Market Session

By Lisa Levin

Today, 3:48 AM

Gainers Chembio Diagnostics, Inc. (NASDAQ: CEMI) shares rose 78.2% to $3.67 in pre-market trading after dropping more than 16% on Tuesday. Chembio’s filing recently showed registration for $60 million common stock offering.

AEHR